Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Fibromyalgia

  • Chapter
  • First Online:
Fibromyalgia Syndrome

Abstract

The pharmacological treatment of fibromyalgia is best considered part of a multimodal approach to management. There are many different agents used in an attempt to ameliorate fibromyalgia symptoms, however few have robust published evidence to support their efficacy in this patient group. Medications are most appropriate when used to target specific illness features, and further research is needed to clarify their roles in this clinically heterogenous syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lawson K. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs. 2016;25(9):1071–81.

    Article  CAS  PubMed  Google Scholar 

  2. Thiagarajah AS, Guymer EK, Leech M, Littlejohn GO. The relationship between fibromyalgia, stress and depression. Int J Clin Rheumatol. 2014;9(4):371–84.

    Article  CAS  Google Scholar 

  3. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114–29.

    Article  CAS  PubMed  Google Scholar 

  4. Rea K, Dinan TG, Cryan JF. The microbiome: a key regulator of stress and neuroinflammation. Neurobiol Stress. 2016;4:23–33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Xanthos DN, Sandkuhler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci. 2014;15(1):43–53.

    Article  CAS  PubMed  Google Scholar 

  6. Napadow V, Kim J, Clauw DJ, Harris RE. Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia. Arthritis Rheum. 2012;64(7):2398–403.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jensen KB, Loitoile R, Kosek E, Petzke F, Carville S, Fransson P, et al. Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. Mol Pain. 2012;8:32.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Harris RE, Sundgren PC, Craig AD, Kirshenbaum E, Sen A, Napadow V, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum. 2009;60(10):3146–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007;11(5):343–51.

    Article  PubMed  Google Scholar 

  10. Harris RE. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther. 2010;12(5):141.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Fayed N, Garcia-Campayo J, Magallon R, Andres-Bergareche H, Luciano JV, Andres E, et al. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Res Ther. 2010;12(4):R134.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol. 2012;242(1–2):33–8.

    Article  CAS  PubMed  Google Scholar 

  13. Kosek E, Martinsen S, Gerdle B, Mannerkorpi K, Lofgren M, Bileviciute-Ljungar I, et al. The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia. Brain Behav Immun. 2016;58:218–27.

    Article  CAS  PubMed  Google Scholar 

  14. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15.

    Article  PubMed  Google Scholar 

  15. Yunus MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. Curr Rheumatol Rev. 2015;11(2):70–85.

    Article  PubMed  Google Scholar 

  16. Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2016;18(1):20–30.

    Article  PubMed  CAS  Google Scholar 

  17. Chinn S, Caldwell W, Gritsenko K. Fibromyalgia pathogenesis and treatment options update. Curr Pain Headache Rep. 2016;20(4):25.

    Article  PubMed  Google Scholar 

  18. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Semin Immunopathol. 2018;40(3):291–300.

    Article  CAS  PubMed  Google Scholar 

  20. Dickenson AH, Sullivan AF. NMDA receptors and central hyperalgesic states. Pain. 1991;46(3):344–6.

    Article  PubMed  Google Scholar 

  21. Staud R, Vierck CJ, Robinson ME, Price DD. Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects. J Pain. 2005;6(5):323–32.

    Article  CAS  PubMed  Google Scholar 

  22. Littlejohn G, Guymer E. Modulation of NMDA receptor activity in fibromyalgia. Biomedicines. 2017;5(2).

    Google Scholar 

  23. Serra J, Collado A, Sola R, Antonelli F, Torres X, Salgueiro M, et al. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol. 2014;75(2):196–208.

    Article  CAS  PubMed  Google Scholar 

  24. Grayston R, Czanner G, Elhadd K, Goebel A, Frank B, Uceyler N, et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: implications for a new paradigm in fibromyalgia etiopathogenesis. Semin Arthritis Rheum. 2019;48(5):933–40.

    Article  PubMed  Google Scholar 

  25. Ruggiero L, Manganelli F, Santoro L. Muscle pain syndromes and fibromyalgia: the role of muscle biopsy. Curr Opin Support Palliat Care. 2018;12(3):382–7.

    Article  PubMed  Google Scholar 

  26. Klaver-Krol EG, Rasker JJ, Klaver MM, Ten Klooster PM, Zwarts MJ. Fibromyalgia: increased reactivity of the muscle membrane and a role of central regulation. Clin Neurophysiol. 2019;130(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  27. Martinez-Martinez LA, Mora T, Vargas A, Fuentes-Iniestra M, Martinez-Lavin M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies. J Clin Rheumatol. 2014;20(3):146–50.

    Article  PubMed  Google Scholar 

  28. Sabharwal R, Rasmussen L, Sluka KA, Chapleau MW. Exercise prevents development of autonomic dysregulation and hyperalgesia in a mouse model of chronic muscle pain. Pain. 2016;157(2):387–98.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Oliveira LR, de Melo VU, Macedo FN, Barreto AS, Badaue-Passos D Jr, Viana dos Santos MR, et al. Induction of chronic non-inflammatory widespread pain increases cardiac sympathetic modulation in rats. Auton Neurosci. 2012;167(1-2):45–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zamuner AR, Barbic F, Dipaola F, Bulgheroni M, Diana A, Atzeni F, et al. Relationship between sympathetic activity and pain intensity in fibromyalgia. Clin Exp Rheumatol. 2015;33(1 Suppl 88):S53–7.

    PubMed  Google Scholar 

  31. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003;30(5):1070–4.

    CAS  PubMed  Google Scholar 

  32. Russell IJ, Perkins AT, Michalek JE, Oxybate SXBFSSG. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2009;60(1):299–309.

    Article  CAS  PubMed  Google Scholar 

  33. Russell IJ, Holman AJ, Swick TJ, Alvarez-Horine S, Wang YG, Guinta D, et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain. 2011;152(5):1007–17.

    Article  CAS  PubMed  Google Scholar 

  34. Spaeth M, Alegre C, Perrot S, Wang Y, Guinta DR, Alvarez-Horine S, et al. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia. Arthritis Res Ther. 2013;15(6):R185.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003;114(7):537–45.

    Article  CAS  PubMed  Google Scholar 

  36. Derry S, Wiffen PJ, Hauser W, Mucke M, Tolle TR, Bell RF, et al. Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults. Cochrane Database Syst Rev. 2017;3:CD012332.

    PubMed  Google Scholar 

  37. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43(2):378–85.

    Article  CAS  PubMed  Google Scholar 

  38. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol. 1995;24(6):360–5.

    Article  CAS  PubMed  Google Scholar 

  40. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9:CD012329.

    PubMed  Google Scholar 

  41. Littlejohn GO, Guymer EK, Ngian GS. Is there a role for opioids in the treatment of fibromyalgia? Pain Manag. 2016;6(4):347–55.

    Article  PubMed  Google Scholar 

  42. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol. 2013;19(2):72–7.

    Article  PubMed  Google Scholar 

  43. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18(1):13–9.

    CAS  PubMed  Google Scholar 

  44. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53(4):519–27.

    Article  PubMed  Google Scholar 

  45. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol. 2000;6(5):250–7.

    Article  CAS  PubMed  Google Scholar 

  46. Baron R, Eberhart L, Kern KU, Regner S, Rolke R, Simanski C, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017;17(5):678–700.

    Article  PubMed  Google Scholar 

  47. van de Donk T, van Velzen M, Dahan A, Niesters M. Cornea nerve fibre state determines analgesic response to tapentadol in fibromyalgia patients without effective endogenous pain modulation. Eur J Pain. 2019;23(9):1586–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Baron R, Likar R, Martin-Mola E, Blanco FJ, Kennes L, Muller M, et al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3B/4 study. Pain Pract. 2016;16(5):580–99.

    Article  PubMed  Google Scholar 

  49. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.

    Article  CAS  PubMed  Google Scholar 

  50. Briscini L, Corradini L, Ongini E, Bertorelli R. Up-regulation of ORL-1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur J Pharmacol. 2002;447(1):59–65.

    Article  CAS  PubMed  Google Scholar 

  51. Chen Y, Sommer C. Nociceptin and its receptor in rat dorsal root ganglion neurons in neuropathic and inflammatory pain models: implications on pain processing. J Peripher Nerv Syst. 2006;11(3):232–40.

    Article  CAS  PubMed  Google Scholar 

  52. Palmisano M, Mercatelli D, Caputi FF, Carretta D, Romualdi P, Candeletti S. N/OFQ system in brain areas of nerve-injured mice: its role in different aspects of neuropathic pain. Genes Brain Behav. 2017;16(5):537–45.

    Article  CAS  PubMed  Google Scholar 

  53. Raffa RB, Burdge G, Gambrah J, Kinecki HE, Lin F, Lu B, et al. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic. J Clin Pharm Ther. 2017;42(1):8–17.

    Article  CAS  PubMed  Google Scholar 

  54. Christoph A, Eerdekens MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017;158(9):1813–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Eerdekens MH, Kapanadze S, Koch ED, Kralidis G, Volkers G, Ahmedzai SH, et al. Cancer-related chronic pain: investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. Eur J Pain. 2019;23(3):577–88.

    Article  CAS  PubMed  Google Scholar 

  56. Dahan A, Boom M, Sarton E, Hay J, Groeneveld GJ, Neukirchen M, et al. Respiratory effects of the nociceptin/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers. Anesthesiology. 2017;126(4):697–707.

    Article  CAS  PubMed  Google Scholar 

  57. Gohler K, Sokolowska M, Schoedel KA, Nemeth R, Kleideiter E, Szeto I, et al. Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study. J Clin Psychopharmacol. 2019;39(1):46–56.

    Article  PubMed  CAS  Google Scholar 

  58. Dagnino APA, da Silva RBM, Chagastelles PC, Pereira TCB, Venturin GT, Greggio S, et al. Nociceptin/orphanin FQ receptor modulates painful and fatigue symptoms in a mouse model of fibromyalgia. Pain. 2019;160(6):1383–401.

    Article  CAS  PubMed  Google Scholar 

  59. Perrot S, Javier RM, Marty M, Le Jeunne C, Laroche F. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology (Oxford). 2008;47(8):1117–23.

    Article  CAS  PubMed  Google Scholar 

  60. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain. 2010;11(6):505–21.

    Article  PubMed  CAS  Google Scholar 

  61. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  62. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum. 1986;29(5):655–9.

    Article  CAS  PubMed  Google Scholar 

  63. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986;29(11):1371–7.

    Article  CAS  PubMed  Google Scholar 

  64. Rico-Villademoros F, Slim M, Calandre EP. Amitriptyline for the treatment of fibromyalgia: a comprehensive review. Expert Rev Neurother. 2015;15(10):1123–50.

    Article  CAS  PubMed  Google Scholar 

  65. Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16(9):1347–68.

    Article  CAS  PubMed  Google Scholar 

  66. Northcott MJ, Guymer EK, Littlejohn GO. Pharmacological treatment options for fibromyalgia. Clinical Pharmacist. 2017;9(11):346–52.

    Google Scholar 

  67. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Care Res. 2004;51(1):9–13.

    Article  CAS  Google Scholar 

  68. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.

    Google Scholar 

  69. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409.

    Article  CAS  PubMed  Google Scholar 

  70. Welsch P, Uceyler N, Klose P, Walitt B, Hauser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018;2:CD010292.

    PubMed  Google Scholar 

  71. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology. 1985;24(12):1211–9.

    Article  CAS  PubMed  Google Scholar 

  72. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–7.

    Article  CAS  PubMed  Google Scholar 

  73. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23(5):255–9.

    Article  CAS  PubMed  Google Scholar 

  74. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia–a randomized, double-blind, placebo-controlled study. Eur J Pain (London). 2000;4(1):27–35.

    Article  CAS  Google Scholar 

  75. Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindl K, Beebe KL, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120(5):448–54.

    Article  CAS  PubMed  Google Scholar 

  76. Walitt B, Urrutia G, Nishishinya MB, Cantrell SE, Hauser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;6:CD011735.

    Google Scholar 

  77. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229–36.

    Article  CAS  PubMed  Google Scholar 

  78. Harris RE, Napadow V, Huggins JP, Pauer L, Kim J, Hampson J, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453–64.

    Article  CAS  PubMed  Google Scholar 

  79. Arnold LM, Choy E, Clauw DJ, Oka H, Whalen E, Semel D, et al. An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr Med Res Opin. 2018;34(8):1397–409.

    Article  CAS  PubMed  Google Scholar 

  80. Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev. 2017;1:CD012188.

    PubMed  Google Scholar 

  81. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin–a meta-analysis of randomized controlled trials. Pain. 2009;145(1-2):69–81.

    Article  PubMed  CAS  Google Scholar 

  82. Calandre EP, Rico-Villademoros F, Slim M. Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother. 2016;16(11):1263–77.

    Article  CAS  PubMed  Google Scholar 

  83. Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019;35(10):1825–35.

    Article  CAS  PubMed  Google Scholar 

  84. Olivan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, Perez-Yus MC, Andres E, Fayed N, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain. 2014;155(12):2517–25.

    Article  CAS  PubMed  Google Scholar 

  85. Fayed N, Olivan B, Lopez Del Hoyo Y, Andres E, Perez-Yus MC, Fayed A, et al. Changes in metabolites in the brain of patients with fibromyalgia after treatment with an NMDA receptor antagonist. Neuroradiol J. 2019;32(6):408–19.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Houck DR, Sindelar L, Sanabria CR, Stanworth SH, Krueger M, Suh M, et al. NYX-2925, a novel N-methyl-D-aspartate receptor modulator: a first-in-human, randomized, double-blind study of safety and pharmacokinetics in adults. Clin Transl Sci. 2019;12(2):164–71.

    Article  CAS  PubMed  Google Scholar 

  87. Ghoreishi-Haack N, Priebe JM, Aguado JD, Colechio EM, Burgdorf JS, Bowers MS, et al. NYX-2925 is a novel N-methyl-D-aspartate receptor modulator that induces rapid and long-lasting analgesia in rat models of neuropathic pain. J Pharmacol Exp Ther. 2018;366(3):485–97.

    Article  CAS  PubMed  Google Scholar 

  88. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7(3):E625–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860–9.

    Article  PubMed  CAS  Google Scholar 

  90. Tzadok R, Ablin JN. Current and emerging pharmacotherapy for fibromyalgia. Pain Res Manag. 2020;2020:6541798.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Sagy I, Bar-Lev Schleider L, Abu-Shakra M, Novack V. Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med. 2019;8(6).

    Google Scholar 

  92. Weber J, Schley M, Casutt M, Gerber H, Schuepfer G, Rukwied R, et al. Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiol Res Pract. 2009;2009.

    Google Scholar 

  93. Ware MA, Wang T, Shapiro S, Collet JP, Team Cs. Cannabis for the management of pain: assessment of safety study (COMPASS). J Pain. 2015;16(12):1233–42.

    Article  PubMed  Google Scholar 

  94. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604–10.

    Article  CAS  PubMed  Google Scholar 

  95. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164–73.

    Article  CAS  PubMed  Google Scholar 

  96. Stockings E, Campbell G, Hall WD, Nielsen S, Zagic D, Rahman R, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018;159(10):1932–54.

    Article  CAS  PubMed  Google Scholar 

  97. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3353–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, et al. Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol Psychiatry. 2018;84(10):722–33.

    Article  CAS  PubMed  Google Scholar 

  99. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction. 2010;105(3):494–503.

    Article  PubMed  Google Scholar 

  100. Ste-Marie PA, Shir Y, Rampakakis E, Sampalis JS, Karellis A, Cohen M, et al. Survey of herbal cannabis (marijuana) use in rheumatology clinic attenders with a rheumatologist confirmed diagnosis. Pain. 2016;157(12):2792–7.

    Article  CAS  PubMed  Google Scholar 

  101. Habib G, Avisar I. The consumption of cannabis by fibromyalgia patients in Israel. Pain Res Treat. 2018;2018:7829427.

    PubMed  PubMed Central  Google Scholar 

  102. Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668–73.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol. 2012;63(6):641–7.

    CAS  PubMed  Google Scholar 

  104. Vidor LP, Torres IL, Custodio de Souza IC, Fregni F, Caumo W. Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study. J Pain Symptom Manag. 2013;46(3):422–32.

    Article  CAS  Google Scholar 

  105. Schwertner A, Conceicao Dos Santos CC, Costa GD, Deitos A, de Souza A, de Souza IC, et al. Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial. Pain. 2013;154(6):874–81.

    Article  CAS  PubMed  Google Scholar 

  106. de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol. 2014;15:40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Castano MY, Garrido M, Rodriguez AB, Gomez MA. Melatonin improves mood status and quality of life and decreases cortisol levels in fibromyalgia. Biol Res Nurs. 2019;21(1):22–9.

    Article  CAS  PubMed  Google Scholar 

  108. Citera G, Arias MA, Maldonado-Cocco JA, Lazaro MA, Rosemffet MG, Brusco LI, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol. 2000;19(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  109. Hussain SA, Al K II, Jasim NA, Gorial FI. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res. 2011;50(3):267–71.

    Article  PubMed  CAS  Google Scholar 

  110. Trofimovitch D, Baumrucker SJ. Pharmacology update: low-dose naltrexone as a possible nonopioid modality for some chronic, nonmalignant pain syndromes. Am J Hosp Palliat Care. 2019;36(10):907–12.

    Article  PubMed  Google Scholar 

  111. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–9.

    Article  CAS  PubMed  Google Scholar 

  112. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–72.

    Article  PubMed  Google Scholar 

  113. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–38.

    Article  CAS  PubMed  Google Scholar 

  114. Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018;14(2):177–80.

    Article  CAS  PubMed  Google Scholar 

  115. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2).

    Google Scholar 

  116. Wightman RS, Nelson LS, Lee JD, Fox LM, Smith SW. Severe opioid withdrawal precipitated by Vivitrol(R). Am J Emerg Med. 2018;36(6):1128.e1-e2.

    Google Scholar 

  117. Chen A, De E, Argoff C. Small fiber polyneuropathy is prevalent in patients experiencing complex chronic pelvic pain. Pain Med. 2019;20(3):521–7.

    Article  PubMed  Google Scholar 

  118. Caro XJ, Winter EF, Dumas AJ. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology (Oxford). 2008;47(2):208–11.

    Article  CAS  PubMed  Google Scholar 

  119. Metyas S, Chen C, Quismorio A, Abdo N, Kamel K. Improvement in fibromyalgia symptoms and skin biopsy results in patients with fibromyalgia related small fiber neuropathy. Curr Rheumatol Rev. 2019.

    Google Scholar 

  120. Goebel A, Netal S, Schedel R, Sprotte G. Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med. 2002;3(2):119–27.

    Article  PubMed  Google Scholar 

  121. Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru. 2019;27(1):149–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Lee YH, Song GG. Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int. 2016;36(5):663–72.

    Article  CAS  PubMed  Google Scholar 

  123. Rico-Villademoros F, Postigo-Martin P, Garcia-Leiva JM, Ordonez-Carrasco JL, Calandre EP. Patterns of pharmacologic and non-pharmacologic treatment, treatment satisfaction and perceived tolerability in patients with fibromyalgia: a patients’ survey. Clin Exp Rheumatol. 2020;38 Suppl 123(1):72–8.

    PubMed  Google Scholar 

  124. Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018;2:CD010585.

    PubMed  Google Scholar 

  125. Gilron I, Chaparro LE, Tu D, Holden RR, Milev R, Towheed T, et al. Combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial. Pain. 2016;157(7):1532–40.

    Article  CAS  PubMed  Google Scholar 

  126. Marlow NM, Simpson KN, Vaughn IA, Jo A, Zoller JS, Short EB. Healthcare costs and medication adherence among patients with fibromyalgia: combination medication vs. duloxetine, milnacipran, venlafaxine, and pregabalin initiators. Pain Pract. 2018;18(2):154–69.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Monash Health, Melbourne, VIC, Australia

    Emma Guymer & Geoffrey Littlejohn

  2. Department of Medicine, Monash University, Melbourne, VIC, Australia

    Emma Guymer & Geoffrey Littlejohn

Authors
  1. Emma Guymer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey Littlejohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma Guymer .

Editor information

Editors and Affiliations

  1. Tel Aviv Sourasky Medical Center & Tel Aviv University School of Medicine, Tel Aviv, Israel

    Jacob N. Ablin

  2. Ariel University, Ariel, Israel

    Yehuda Shoenfeld

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Guymer, E., Littlejohn, G. (2021). Pharmacological Treatment of Fibromyalgia. In: Ablin, J.N., Shoenfeld, Y. (eds) Fibromyalgia Syndrome . Springer, Cham. https://doi.org/10.1007/978-3-030-78638-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-78638-0_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-78637-3

  • Online ISBN: 978-3-030-78638-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation